推荐英文药学书Color atlas of pharmacology

Color Atlas of
Pharmacology
2nd edition, revised and expanded
Heinz Lüllmann, M. D.
Professor Emeritus
Department of Pharmacology
University of Kiel
Germany
Klaus Mohr, M. D.
Professor
Department of Pharmacology
and Toxicology
Institute of Pharmacy
University of Bonn
Germany
Albrecht Ziegler, Ph.D.
Professor
Department of Pharmacology
University of Kiel
Germany
Detlef Bieger, M. D.
Professor
Division of Basic Medical Sciences
Faculty of Medicine
Memorial University of
Newfoundland
St. John’s, Newfoundland
Canada
164 color plates by Jürgen Wirth
Thieme
Stuttgart · New York · 2000
Lüllmann, Color Atlas of Pharmacology © 2000 Thieme
All rights reserved. Usage subject to terms and conditions of license.
IV
Illustrated by Jürgen Wirth, Darmstadt, Germany
This book is an authorized revised and expanded
translation of the 3rd German edition
published and copyrighted 1996 by Georg
Thieme Verlag, Stuttgart, Germany. Title of the
German edition:
Taschenatlas der Pharmakologie
Some of the product names, patents and registered
designs referred to in this book are in
fact registered trademarks or proprietary
names even though specific reference to this
fact is not always made in the text. Therefore,
the appearance of a name without designation
as proprietary is not to be construed as a
representation by the publisher that it is in the
public domain.
This book, including all parts thereof, is legally
protected by copyright. Any use, exploitation
or commercialization outside the narrow limits
set by copyright legislation, without the
publisher’s consent, is illegal and liable to
prosecution. This applies in particular to photostat
reproduction, copying, mimeographing
or duplication of any kind, translating, preparation
of microfilms, and electronic data processing
and storage.
©2000 Georg Thieme Verlag, Rüdigerstrasse14,
D-70469 Stuttgart, Germany
Thieme New York, 333 Seventh Avenue, New
York, NY 10001, USA
Typesetting by Gulde Druck, Tübingen
Printed in Germany by Staudigl, Donauwörth
ISBN 3-13-781702-1 (GTV)
ISBN 0-86577-843-4 (TNY) 1 2 3 4 5 6
Important Note: Medicine is an ever-changing
science undergoing continual development.
Research and clinical experience are
continually expanding our knowledge, in particular
our knowledge of proper treatment and
drug therapy. Insofar as this book mentions
any dosage or application, readers may rest assured
that the authors, editors and publishers
have made every effort to ensure that such references
are in accordance with the state of
knowledge at the time of production of the
book.
Nevertheless this does not involve, imply, or
express any guarantee or responsibility on the
part of the publishers in respect of any dosage
instructions and forms of application stated in
the book. Every user is requested to examine
carefully the manufacturers’ leaflets accompanying
each drug and to check, if necessary in
consultation with a physician or specialist,
whether the dosage schedules mentioned
therein or the contraindications stated by the
manufacturers differ from the statements
made in the present book. Such examination is
particularly important with drugs that are
either rarely used or have been newly released
on the market. Every dosage schedule or every
form of application used is entirely at the
user’s own risk and responsibility. The authors
and publishers request every user to report
to the publishers any discrepancies or inaccuracies
noticed.
Lüllmann, Color Atlas of Pharmacology © 2000 Thieme
All rights reserved. Usage subject to terms and conditions of license
Preface
The present second edition of the Color Atlas of Pharmacology goes to print six years
after the first edition. Numerous revisions were needed, highlighting the dramatic
continuing progress in the drug sciences. In particular, it appeared necessary to include
novel therapeutic principles, such as the inhibitors of platelet aggregation
from the group of integrin GPIIB/IIIA antagonists, the inhibitors of viral protease, or
the non-nucleoside inhibitors of reverse transcriptase. Moreover, the re-evaluation
and expanded use of conventional drugs, e.g., in congestive heart failure, bronchial
asthma, or rheumatoid arthritis, had to be addressed. In each instance, the primary
emphasis was placed on essential sites of action and basic pharmacological principles.
Details and individual drug properties were deliberately omitted in the interest
of making drug action more transparent and affording an overview of the pharmacological
basis of drug therapy.
The authors wish to reiterate that the Color Atlas of Pharmacology cannot replace a
textbook of pharmacology, nor does it aim to do so. Rather, this little book is designed
to arouse the curiosity of the pharmacological novice; to help students of medicine
and pharmacy gain an overview of the discipline and to review certain bits of
information in a concise format; and, finally, to enable the experienced therapist to
recall certain factual data, with perhaps some occasional amusement.
Our cordial thanks go to the many readers of the multilingual editions of the Color
Atlas for their suggestions. We are indebted to Prof. Ulrike Holzgrabe, Würzburg,
Doc. Achim Meißner, Kiel, Prof. Gert-Hinrich Reil, Oldenburg, Prof. Reza Tabrizchi, St.
John’s, Mr Christian Klein, Bonn, and Mr Christian Riedel, Kiel, for providing stimulating
and helpful discussions and technical support, as well as to Dr. Liane Platt-
Rohloff, Stuttgart, and Dr. David Frost, New York, for their editorial and stylistic guidance.
Heinz Lüllmann
Klaus Mohr
Albrecht Ziegler
Detlef Bieger
Jürgen Wirth
Contents
General Pharmacology . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . 1
History of Pharmacology . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . 2
Drug Sources
Drug and Active Principle . . . . . . . . . . .. . . . . . . . . . . . . . . . . . 4
Drug Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Drug Administration
Dosage Forms for Oral, and Nasal Applications . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Dosage Forms for Parenteral Pulmonary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Rectal or Vaginal, and Cutaneous Application . . . . . . . . . .. . . . . . . . . . 12
Drug Administration by Inhalation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Dermatalogic Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
From Application to Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Cellular Sites of Action
Potential Targets of Drug Action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Distribution in the Body
External Barriers of the Body . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Blood-Tissue Barriers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Membrane Permeation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
Possible Modes of Drug Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Binding to Plasma Proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
Drug Elimination
The Liver as an Excretory Organ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Biotransformation of Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Enterohepatic Cycle . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . 38
The Kidney as Excretory Organ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Elimination of Lipophilic and Hydrophilic Substances . . . . . . . . . . . . . . . . . . . . . 42
Pharmacokinetics
Drug Concentration in the Body as a Function of Time.
First-Order (Exponential) Rate Processes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Time Course of Drug Concentration in Plasma . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Time Course of Drug Plasma Levels During Repeated
Dosing and During Irregular Intake . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Accumulation: Dose, Dose Interval, and Plasma Level Fluctuation . . . . . . . . . . 50
Change in Elimination Characteristics During Drug Therapy . . . . . . . . . . . . . . . 50
Quantification of Drug Action
Dose-Response Relationship . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . 52
Concentration-Effect Relationship – Effect Curves . . . . . . . . . . . . . . . . . . . . . . . . 54
Concentration-Binding Curves . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Drug-Receptor Interaction
Types of Binding Forces . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
Agonists-Antagonists . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . 60
Enantioselectivity of Drug Action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Receptor Types . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . 64
Mode of Operation of G-Protein-Coupled Receptors . . . . . . . . . . . . . . . . . . . . . . 66
Time Course of Plasma Concentration and Effect . . . . . . . . . . . . . . . . . . . . . . . . . 68
Adverse Drug Effects . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . 70
Drug Allergy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
Drug Toxicity in Pregnancy and Lactation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
Drug-independent Effects
Placebo – Homeopathy . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . 76
Systems Pharmacology . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . 79
Drug Acting on the Sympathetic Nervous System
Sympathetic Nervous System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
Structure of the Sympathetic Nervous System . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Adrenoceptor Subtypes and Catecholamine Actions . . . . . . . . . . . . . . . . . . . . . . 84
Structure – Activity Relationship of Sympathomimetics . . . . . . . . . . . . . . . . . . . 86
Indirect Sympathomimetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
α-Sympathomimetics, α-Sympatholytics . . . . . . . . . . . . . . . . . . . . . . . 90
β-Sympatholytics (β-Blockers) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
Types of β-Blockers . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . 94
Antiadrenergics . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
Drugs Acting on the Parasympathetic Nervous System
Parasympathetic Nervous System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
Cholinergic Synapse . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . 100
Parasympathomimetics . . . . . . .  . . . . . . . . . . . . . . . . . . . . . 102
Parasympatholytics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
Nicotine
Ganglionic Transmission . . . . . . . . . . .  . . . . . . . . . . . . . . . . . 108
Effects of Nicotine on Body Functions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Consequences of Tobacco Smoking . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
Biogenic Amines
Biogenic Amines – Actions and
Pharmacological Implications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Serotonin . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . 116
Vasodilators
Vasodilators – Overview . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . 118
Organic Nitrates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
Calcium Antagonists . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . 122
Inhibitors of the RAA System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
Drugs Acting on Smooth Muscle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Drugs Used to Influence Smooth Muscle Organs . . . . . . . . . . . . . . . . . . . . . . . . . . 126
Cardiac Drugs
Overview of Modes of Action . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
Cardiac Glycosides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
Antiarrhythmic Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
Electrophysiological Actions of Antiarrhythmics of
the Na+-Channel Blocking Type . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Antianemics
Drugs for the Treatment of Anemias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
Iron Compounds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140
Antithrombotics
Prophylaxis and Therapy of Thromboses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
Coumarin Derivatives – Heparin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
Fibrinolytic Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
Intra-arterial Thrombus Formation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
Formation, Activation, and Aggregation of Platelets . . . . . . . . . . . . . . . . . . . . . . . 148
Inhibitors of Platelet Aggregation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
Presystemic Effect of Acetylsalicylic Acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
Adverse Effects of Antiplatelet Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
Plasma Volume Expanders . . . . . . . . . . . .. . . . . . . . . . . . . . . . . 152
Drugs used in Hyperlipoproteinemias
Lipid-Lowering Agents . . . . . . . . . . . . . .. . . . . . . . . . . . . 154
Diuretics
Diuretics – An Overview . . . . . . . . . . . . . . . . . . . . . . . . 158
NaCI Reabsorption in the Kidney . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
Osmotic Diuretics . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . 160
Diuretics of the Sulfonamide Type . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
Potassium-Sparing Diuretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
Antidiuretic Hormone (/ADH) and Derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
Drugs for the Treatment of Peptic Ulcers
Drugs for Gastric and Duodenal Ulcers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
Laxatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170
Antidiarrheals
Antidiarrheal Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 178
Other Gastrointestinal Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180
Drugs Acting on Motor Systems
Drugs Affecting Motor Function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 182
Muscle Relaxants . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . 184
Depolarizing Muscle Relaxants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
Antiparkinsonian Drugs . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . 188
Antiepileptics . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
Drugs for the Suppression of Pain, Analgesics,
Pain Mechanisms and Pathways . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194
Antipyretic Analgesics
Eicosanoids . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196
Antipyretic Analgesics and Antiinflammatory Drugs
Antipyretic Analgesics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 198
Antipyretic Analgesics
Nonsteroidal Antiinflammatory
(Antirheumatic) Agents . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . 200
Thermoregulation and Antipyretics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
Local Anesthetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
Opioids
Opioid Analgesics – Morphine Type . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210
General Anesthetic Drugs
General Anesthesia and General Anesthetic Drugs . . . . . . . . . . . . . . . . . . . . . . . . 216
Inhalational Anesthetics . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . 218
Injectable Anesthetics . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . 220
Hypnotics
Soporifics, Hypnotics . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . 222
Sleep-Wake Cycle and Hypnotics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 224
Psychopharmacologicals
Benzodiazepines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226
Pharmacokinetics of Benzodiazepines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228
Therapy of Manic-Depressive Illnes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230
Therapy of Schizophrenia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236
Psychotomimetics (Psychedelics, Hallucinogens) . . . . . . . . . . . . . . . . . . . . . . . . . 240
Hormones
Hypothalamic and Hypophyseal Hormones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 242
Thyroid Hormone Therapy . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . 244
Hyperthyroidism and Antithyroid Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 246
Glucocorticoid Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248
Androgens, Anabolic Steroids, Antiandrogens . . . . . . . .. . . . . . . . . . . . . . . 252
Follicular Growth and Ovulation, Estrogen and
Progestin Production . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . 254
Oral Contraceptives . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . 256
Insulin Therapy . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . 258
Treatment of Insulin-Dependent
Diabetes Mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 260
Treatment of Maturity-Onset (Type II)
Diabetes Mellitus . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . 262
Drugs for Maintaining Calcium Homeostasis . . . . . . . . .  . . . . . 264
Antibacterial Drugs
Drugs for Treating Bacterial Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266
Inhibitors of Cell Wall Synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 268
Inhibitors of Tetrahydrofolate Synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 272
Inhibitors of DNA Function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 274
Inhibitors of Protein Synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 276
Drugs for Treating Mycobacterial Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 280
Antifungal Drugs
Drugs Used in the Treatment of Fungal Infection . . . . . . . . . . . . . . . . . . . . . . . . . 282
Antiviral Drugs
Chemotherapy of Viral Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 284
Drugs for Treatment of AIDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 288
Disinfectants
Disinfectants and Antiseptics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 290
Antiparasitic Agents
Drugs for Treating Endo- and Ectoparasitic Infestations . . . . . . . . . . . . . . . . . . . 292
Antimalarials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 294
Anticancer Drugs
Chemotherapy of Malignant Tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 296
Immune Modulators
Inhibition of Immune Responses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300
Antidotes
Antidotes and treatment of poisonings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302
Therapy of Selected Diseases
Angina Pectoris . . . . . . . . . . . . . . . . .  .  . . . . . . . . . . . . . . . . . . . . 306
Antianginal Drugs . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . 308
Acute Myocardial Infarction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 310
Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 312
Hypotension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 314
Gout . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 316
Osteoporosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 318
Rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 320
Migraine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 322
Common Cold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 324
Allergic Disorders . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 326
Bronchial Asthma . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . 328
Emesis . . . . . . . . . . .  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 330

Further Reading . . . . . . .. . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . 332
Drug Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 334
Index . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 368

要是有全书全文就好了，楼主可不可以发一个啊，谢谢

楼主可以让大家见识见识吗？

同意两位的看法